Hemostasis Today

July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Heghine Khachatryan: How Well Do We Recognize Anti-PF4 Disorders?
Jul 20, 2026, 14:33

Heghine Khachatryan: How Well Do We Recognize Anti-PF4 Disorders?

Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared Shinya Goto‘s post on LinkedIn:

“An outstanding and highly relevant review on platelet-activating anti-PF4 disorders.

For practicing clinicians, these immune-mediated thrombotic syndromes are no longer rare academic entities.

HIT, autoimmune HIT, spontaneous HIT, VITT, and VITT-like disorders are increasingly recognized across diverse clinical settings, making early suspicion, timely laboratory diagnosis, and prompt initiation of appropriate therapy essential for improving patient outcomes.

This review provides an excellent synthesis of current concepts in the pathophysiology, diagnosis, and management of anti-PF4 disorders and will undoubtedly become an important reference for physicians involved in thrombosis, hemostasis, intensive care, hematology, and vascular medicine.

Congratulations to the authors on this outstanding contribution to the field.”

Shinya Goto, Director and Chairman in Metabolic Disease Research Center, shared a post on LinkedIn about a recent article by Theodore E. Warkentin et al., published in NEJM, adding:

“Very good review regarding Platelet-Activating Anti–Platelet Factor 4 Disorders including HIT!”

Title: Very good review regarding Platelet-Activating Anti–Platelet Factor 4 Disorders including HIT!

Authors: Theodore E. Warkentin, Andreas Greinacher

Heghine Khachatryan: How Well Do We Recognize Anti-PF4 Disorders?

Other posts featuring Heghine Khachatryan on Hemostasis Today.